Immunodeficiency and the risk of serious clinical endpoints in a well studied cohort of treated HIV-infected patients. - Wikidata - wikimedia - TriplyDB

Immunodeficiency and the risk of serious clinical endpoints in a well studied cohort of treated HIV-infected patients.

Immunodeficiency and the risk of serious clinical endpoints in a well studied cohort of treated HIV-infected patients.

http://www.wikidata.org/entity/Q33987654

about

Targeting the Brain Reservoirs: Toward an HIV Cure The clinical impact of continuing to prescribe antiretroviral therapy in patients with advanced AIDS who manifest no virologic or immunologic benefit The VACS index accurately predicts mortality and treatment response among multi-drug resistant HIV infected patients participating in the options in management with antiretrovirals (OPTIMA) study Reclassification of risk of death with the knowledge of D-dimer in a cohort of treated HIV-infected individuals.Risk of all-cause mortality in HIV infected patients is associated with clinical, immunologic predictors and the CCR5 Δ32 deletion Residual immune dysregulation syndrome in treated HIV infection.Depression and sexual dysfunction among HIV-positive and HIV-negative men who have sex with men: mediation by use of antidepressants and recreational stimulants Late HIV diagnosis is a major risk factor for intensive care unit admission in HIV-positive patients: a single centre observational cohort study Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America.When to start antiretroviral therapy: the need for an evidence base during early HIV infection Change in fibrosis score as a predictor of mortality among HIV-infected patients with viral hepatitis.Progression of carotid intima-media thickness in a contemporary human immunodeficiency virus cohort Circulating microRNAs in Sera Correlate with Soluble Biomarkers of Immune Activation but Do Not Predict Mortality in ART Treated Individuals with HIV-1 Infection: A Case Control Study Assessment of the impact of adherence and other predictors during HAART on various CD4 cell responses in resource-limited settings.The Clinical Significance of CD4 Counts in Asian and Caucasian HIV-Infected Populations: Results from TAHOD and AHOD HIV infection and coronary heart disease: an intersection of epidemics Relevance of Interleukin-6 and D-Dimer for Serious Non-AIDS Morbidity and Death among HIV-Positive Adults on Suppressive Antiretroviral Therapy.Balancing immunological benefits and cardiovascular risks of antiretroviral therapy: when is immediate treatment optimal?Risk factors for chronic kidney disease in a large cohort of HIV-1 infected individuals initiating antiretroviral therapy in routine care.Incidence and clinical features of cerebrovascular disease among HIV-infected adults in the Southeastern United States.Early postseroconversion CD4 cell counts independently predict CD4 cell count recovery in HIV-1-postive subjects receiving antiretroviral therapy High risk of obesity and weight gain for HIV-infected uninsured minorities.RYR3 gene variants in subclinical atherosclerosis among HIV-infected women in the Women's Interagency HIV Study (WIHS).Renal issues in HIV infection.Management of fat accumulation in patients with HIV infection.Considerations for Endpoint Selection When Designing HIV Clinical Trials.Achieving a cure for HIV infection: do we have reasons to be optimistic?Interleukin-7 and immune reconstitution in cancer patients: a new paradigm for dramatically increasing overall survival Epidemiology of ischemic heart disease in HIV.Predictors of immune recovery and the association with late mortality while on antiretroviral treatment in Cambodia.Prediction of long-term outcomes of HIV-infected patients developing non-AIDS events using a multistate approach.Impact of early versus deferred antiretroviral therapy on estimated glomerular filtration rate in HIV-positive individuals in the START trial.Pre-therapy inflammation and coagulation activation and long-term CD4 count responses to the initiation of antiretroviral therapy.Late diagnosis of human immunodeficiency virus infection in patients with viral hepatitis.Kidney Disease in HIV-Infected Persons.All-cause mortality in treated HIV-infected adults with CD4 ≥500/mm3 compared with the general population: evidence from a large European observational cohort collaboration.British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015 Race and CD4+T-cell count in HIV prognosis and treatment

P2860

Q28075694-C1E16757-8B08-4E2F-A5A3-F07771FAB622 Q28535156-A67F5547-4ABB-453B-AA31-ABA9E13922D4 Q28541478-D3F03FCF-8EEC-4B69-B767-644D664FF7E9 Q33917180-1F48CC71-5270-481C-8983-65CC20A1B499 Q33971366-9BD68A61-2B31-409D-BD65-099F317E1039 Q34020121-F2469E10-A7B7-4BA0-B7EE-33288A91788E Q34255703-482EB507-0973-452C-B68D-76686E31AE92 Q34554118-7DBD42A4-6C04-495B-A65A-4E4129DA8F28 Q34736194-27493D84-0649-4D82-8C44-1C537ADD8C0A Q34773308-3E71933D-29CF-447A-B309-680A630083B5 Q35180503-D699516C-D6BC-4601-A64A-C3A66EE50525 Q35215672-1AC83D5C-AD45-457C-8395-361BD3A81428 Q35806035-582BB43E-B329-4C82-B118-8C3152BEA7EC Q35905907-4BAB699E-0670-4A43-A05C-F0E70334A8A9 Q35916153-6C85485A-5DA2-4448-B845-7D58D917F9E9 Q35949941-95642532-5FF1-4836-8403-B756E3EC9902 Q36015621-C61C5C42-1EEA-4112-AAC1-8061D91C75BF Q36338387-13240530-A88D-43B3-972A-98788B5127B0 Q36492436-CC03B6BD-AC9F-4FDE-B67B-7EC72A67128D Q36937890-33B3C3F0-F96A-413E-94C3-1067E69D59C0 Q37207042-00A02987-CD44-4D29-91A3-BC36A6702A59 Q37642702-1213BA81-1214-4CB2-B30A-8842BD0FC5DB Q37662724-0CB8F655-F245-40CC-9CCD-82AF993D15FA Q37885232-E9A84877-7914-4017-A3DF-68031FCD37B9 Q37899071-86FE3102-F664-451C-9226-96D22E2DD3D4 Q37967498-00CA2E85-87F0-40EC-8ADC-27B8A2186AA4 Q37980423-BAD20774-A06A-42F3-B3DE-261A1676C8F4 Q37989867-20BDDA0F-8FF8-4A01-A064-54DDFF682358 Q38629009-52F643B3-94E2-41F1-AAB0-670B3D3C5C2E Q39550582-FE53B6B1-C2BA-4225-BAC4-8BE9CC11A36D Q40060299-F90878AB-0E37-4C5F-AECB-5AB424A3729F Q40150734-49DF1586-1D53-448E-97AA-C0D18B0F4B6D Q40954848-76A65B6F-BD01-479D-BEC1-D35DF6A244DD Q45350855-2B272DD6-941F-4667-96E8-CEDA09DDDD1C Q46653347-9D465052-55F6-4EE2-9565-255CBE862ABC Q47918470-7C9D7196-F8FB-4005-89AC-8DEF7F90A5C9 Q57180790-7F14466E-0A95-40AD-A9C7-FF8D8E74A0FC Q58033132-45BF73C1-3AF8-44B2-931C-A83D3CB4A0B5

P2860

Immunodeficiency and the risk of serious clinical endpoints in a well studied cohort of treated HIV-infected patients.

http://www.wikidata.org/entity/Q33987654

description

2010 nî lūn-bûn

@nan

2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Immunodeficiency and the risk ...... treated HIV-infected patients.

@ast

Immunodeficiency and the risk ...... treated HIV-infected patients.

@en

type

label

Immunodeficiency and the risk ...... treated HIV-infected patients.

@ast

Immunodeficiency and the risk ...... treated HIV-infected patients.

@en

prefLabel

Immunodeficiency and the risk ...... treated HIV-infected patients.

@ast

Immunodeficiency and the risk ...... treated HIV-infected patients.

@en

P1433

Q33987654-C6ACDB44-B1E7-4E96-9755-0C0C090DCA6C

P1476

Q33987654-A9040B9C-A045-459B-A864-791E9F2A19BE

P2093

Q33987654-22B37EBF-BE95-4BC8-BF21-291BE3EAE73A

Q33987654-81563600-246F-4908-9429-F86F5957BBAC

Q33987654-836C6F15-BF10-4268-980A-1673F86F30B1

Q33987654-9449F96A-2C56-4875-98F2-1A5FE070AE79

Q33987654-A662CBDC-185E-4E2B-8802-094DADB9F81D

Q33987654-BE7B0778-3815-4679-8819-4F9B35A164A1

Q33987654-CA512CA6-D587-4B89-8D49-D04ECF767967

Q33987654-DE613850-0932-4481-97F3-FD480F86B80D

P2860

Q33987654-02601315-3219-4B73-A384-745C45A040A3

Q33987654-167B3A06-CE55-4990-BA83-ABC86AF2974B

Q33987654-21BF3107-4F14-4A89-B13F-E7F62576A428

Q33987654-247C6245-A6A5-4B23-9A6C-098DE99C5DE6

Q33987654-2E6FA710-AAA0-4ACE-9AAE-FAB79896D2DF

Q33987654-35BB0F56-76E5-480A-92EE-7BB9B267624C

Q33987654-3AEDDEE2-DFCF-490D-A140-25E0E19A69FF

Q33987654-47AC66AC-5FB8-4406-9AFA-00DFE06A208B

Q33987654-53C117D6-AA18-485D-B7FC-67030B7EA57D

Q33987654-5C4D30C9-504E-47BC-BB2E-8D4452247CB1

P304

Q33987654-A677E741-FFE1-4EC7-B5B6-685317B2E90C

P31

Q33987654-030454D5-4639-4386-A0B3-A9105C6B34DE

P356

Q33987654-ED643A70-0027-4B63-8831-85C072B72095

P407

Q33987654-9E9B5F07-9A7B-495A-B6E7-E935536A974C

P433

Q33987654-8B0956DD-12A9-4CA5-AC29-0D74A114BF95

P478

Q33987654-7770FA67-5A80-4E45-942F-C6C9BF05905B

P50

Q33987654-1C1F11A6-FF33-4425-9BAA-5C771649C6B8

Q33987654-C6038B07-AFF7-4AFA-B383-8039ABDE2A4A

P577

Q33987654-8888EC82-98E3-45D4-A964-F8740E57C974

P698

Q33987654-F07C2D4B-7DD9-43B4-B0DF-D7C4B95AFF77

P932

Q33987654-DF0B9080-8295-4138-B4DF-6B950677F337

P356

QAD.0B013E32833B1B26

P1433

P1476

Immunodeficiency and the risk ...... treated HIV-infected patients.

@en

P2093

Amit C Achhra

http://www.w3.org/2001/XMLSchema#string

David A Cooper

http://www.w3.org/2001/XMLSchema#string

Fred M Gordin

http://www.w3.org/2001/XMLSchema#string

INSIGHT ESPRIT & SILCAAT study groups

http://www.w3.org/2001/XMLSchema#string

James D Neaton

http://www.w3.org/2001/XMLSchema#string

Jan Gerstoft

http://www.w3.org/2001/XMLSchema#string

Matthew G Law

http://www.w3.org/2001/XMLSchema#string

Michael J Vjecha

http://www.w3.org/2001/XMLSchema#string

P2860

Inflammatory and coagulation biomarkers and mortality in patients with HIV infection

CD4+ count-guided interruption of antiretroviral treatment

Incidence and risk factors for the occurrence of non-AIDS-defining cancers among human immunodeficiency virus-infected individuals.

Increase in non-AIDS related conditions as causes of death among HIV-infected individuals in the HAART era in Brazil.

Pretreatment CD4 cell slope and progression to AIDS or death in HIV-infected patients initiating antiretroviral therapy--the CASCADE collaboration: a collaboration of 23 cohort studies.

Interleukin-2 therapy in patients with HIV infection.

Risk of all-cause mortality associated with nonfatal AIDS and serious non-AIDS events among adults infected with HIV.

Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group.

Role of uncontrolled HIV RNA level and immunodeficiency in the occurrence of malignancy in HIV-infected patients during the combination antiretroviral therapy era: Agence Nationale de Recherche sur le Sida (ANRS) CO3 Aquitaine Cohort.

Elevated risk of lung cancer among people with AIDS.

P304

1877-1886

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/QAD.0B013E32833B1B26

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

24

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20588170

http://www.w3.org/2001/XMLSchema#string

P932

2902669

http://www.w3.org/2001/XMLSchema#string